Aravive Announces Approximately $41.5 Million Private Placement Financing
October 25, 2022 07:30 ET
|
Aravive, Inc.
HOUSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) (“Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced...
Aravive Receives Third Development Milestone from 3D Medicines
October 10, 2022 16:05 ET
|
Aravive, Inc.
HOUSTON, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced...
Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference
September 26, 2022 08:00 ET
|
Aravive, Inc.
HOUSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 16:05 ET
|
Aravive, Inc.
HOUSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that...
Aravive Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
August 11, 2022 07:00 ET
|
Aravive, Inc.
Hosted Key Opinion Leader (KOL) Symposium; KOLs Presented Positive Updated Batiraxcept Phase 1b Clear Cell Renal Cell Carcinoma (ccRCC) and Phase 1b Pancreatic Adenocarcinoma Data.Presented Updated...
Aravive Appoints Dr. Robert B. Geller as Chief Medical Officer
July 05, 2022 09:07 ET
|
Aravive, Inc.
HOUSTON, July 05, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Appoints Rudy Howard as Chief Financial Officer
June 03, 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Aravive Presents Updated Clinical Data at ASCO Showing Continued Best-in-Class Potential of Batiraxcept in Advanced or Metastatic clear cell Renal Cell Carcinoma (ccRCC)
May 26, 2022 17:11 ET
|
Aravive, Inc.
Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022Development of biomarker offers the potential of a first in class targeted therapy in renal cancerCompany has a...
Aravive to Participate in H.C. Wainwright Global Investment Conference
May 17, 2022 07:00 ET
|
Aravive, Inc.
HOUSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail...
Aravive Reports First Quarter 2022 Financial Results and Provides Corporate Updates
May 12, 2022 07:00 ET
|
Aravive, Inc.
Reported positive updated data and new biomarker data from Phase 1b Study of Batiraxcept in ccRCCPresented updated modeling data from batiraxcept clinical trials at the AACR annual meeting Dosed...